ID   LATS1_HUMAN             Reviewed;        1130 AA.
AC   O95835; Q6PKD0;
DT   27-SEP-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   12-OCT-2022, entry version 205.
DE   RecName: Full=Serine/threonine-protein kinase LATS1;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:10518011, ECO:0000269|PubMed:15122335};
DE   AltName: Full=Large tumor suppressor homolog 1;
DE   AltName: Full=WARTS protein kinase;
DE            Short=h-warts;
GN   Name=LATS1 {ECO:0000312|EMBL:AAD16882.1};
GN   Synonyms=WARTS {ECO:0000312|EMBL:AAD50272.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAD16882.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), PHOSPHORYLATION, AND INTERACTION
RP   WITH CDK1.
RC   TISSUE=Fetal brain {ECO:0000312|EMBL:AAD16882.1};
RX   PubMed=9988268; DOI=10.1038/5960;
RA   Tao W., Zhang S., Turenchalk G.S., Stewart R.A., St John M.A., Chen W.,
RA   Xu T.;
RT   "Human homologue of the Drosophila melanogaster lats tumour suppressor
RT   modulates CDC2 activity.";
RL   Nat. Genet. 21:177-181(1999).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:AAD50272.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND PHOSPHORYLATION.
RX   PubMed=10518011; DOI=10.1016/s0014-5793(99)01224-7;
RA   Nishiyama Y., Hirota T., Morisaki T., Hara T., Marumoto T., Iida S.,
RA   Makino K., Yamamoto H., Hiraoka T., Kitamura N., Saya H.;
RT   "A human homolog of Drosophila warts tumor suppressor, h-warts, localized
RT   to mitotic apparatus and specifically phosphorylated during mitosis.";
RL   FEBS Lett. 459:159-165(1999).
RN   [3] {ECO:0000305, ECO:0000312|EMBL:AAH02767.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Endometrium {ECO:0000312|EMBL:AAH02767.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4] {ECO:0000305}
RP   FUNCTION, AND INTERACTION WITH ZYX.
RX   PubMed=10831611; DOI=10.1083/jcb.149.5.1073;
RA   Hirota T., Morisaki T., Nishiyama Y., Marumoto T., Tada K., Hara T.,
RA   Masuko N., Inagaki M., Hatakeyama K., Saya H.;
RT   "Zyxin, a regulator of actin filament assembly, targets the mitotic
RT   apparatus by interacting with h-warts/LATS1 tumor suppressor.";
RL   J. Cell Biol. 149:1073-1086(2000).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [6] {ECO:0000305}
RP   FUNCTION, CATALYTIC ACTIVITY, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF
RP   LYS-734.
RX   PubMed=15122335; DOI=10.1038/sj.onc.1207623;
RA   Iida S., Hirota T., Morisaki T., Marumoto T., Hara T., Kuninaka S.,
RA   Honda S., Kosai K., Kawasuji M., Pallas D.C., Saya H.;
RT   "Tumor suppressor WARTS ensures genomic integrity by regulating both
RT   mitotic progression and G1 tetraploidy checkpoint function.";
RL   Oncogene 23:5266-5274(2004).
RN   [7] {ECO:0000305}
RP   FUNCTION, AND INTERACTION WITH LIMK1.
RX   PubMed=15220930; DOI=10.1038/ncb1140;
RA   Yang X., Yu K., Hao Y., Li D.-M., Stewart R.A., Insogna K.L., Xu T.;
RT   "LATS1 tumour suppressor affects cytokinesis by inhibiting LIMK1.";
RL   Nat. Cell Biol. 6:609-617(2004).
RN   [8]
RP   PHOSPHORYLATION AT SER-909 AND THR-1079.
RX   PubMed=15688006; DOI=10.1038/sj.onc.1208445;
RA   Chan E.H.Y., Nousiainen M., Chalamalasetty R.B., Schaefer A., Nigg E.A.,
RA   Sillje H.H.W.;
RT   "The Ste20-like kinase Mst2 activates the human large tumor suppressor
RT   kinase Lats1.";
RL   Oncogene 24:2076-2086(2005).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-674, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III, Hurov K.E.,
RA   Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y.,
RA   Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [10]
RP   FUNCTION, INTERACTION WITH YAP1, AND MUTAGENESIS OF TYR-559.
RX   PubMed=18158288; DOI=10.1074/jbc.m709037200;
RA   Hao Y., Chun A., Cheung K., Rashidi B., Yang X.;
RT   "Tumor suppressor LATS1 is a negative regulator of oncogene YAP.";
RL   J. Biol. Chem. 283:5496-5509(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-246; SER-278 AND SER-464, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [16]
RP   INTERACTION WITH LIMD1; WTIP AND AJUBA.
RX   PubMed=20303269; DOI=10.1016/j.cub.2010.02.035;
RA   Das Thakur M., Feng Y., Jagannathan R., Seppa M.J., Skeath J.B.,
RA   Longmore G.D.;
RT   "Ajuba LIM proteins are negative regulators of the Hippo signaling
RT   pathway.";
RL   Curr. Biol. 20:657-662(2010).
RN   [17]
RP   INTERACTION WITH MOB1A AND MOB1B.
RX   PubMed=19739119; DOI=10.1002/ijc.24878;
RA   Chow A., Hao Y., Yang X.;
RT   "Molecular characterization of human homologs of yeast MOB1.";
RL   Int. J. Cancer 126:2079-2089(2010).
RN   [18]
RP   FUNCTION, PHOSPHORYLATION AT SER-464, AND MUTAGENESIS OF SER-464.
RX   PubMed=19927127; DOI=10.1038/emboj.2009.342;
RA   Humbert N., Navaratnam N., Augert A., Da Costa M., Martien S., Wang J.,
RA   Martinez D., Abbadie C., Carling D., de Launoit Y., Gil J., Bernard D.;
RT   "Regulation of ploidy and senescence by the AMPK-related kinase NUAK1.";
RL   EMBO J. 29:376-386(2010).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-246; SER-464 AND SER-613, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   INTERACTION WITH STK3, AND PHOSPHORYLATION AT THR-1079.
RX   PubMed=28087714; DOI=10.1101/gad.284539.116;
RA   Kwan J., Sczaniecka A., Arash E.H., Nguyen L., Chen C.C., Ratkovic S.,
RA   Klezovitch O., Attisano L., McNeill H., Emili A., Vasioukhin V.;
RT   "DLG5 connects cell polarity and Hippo signaling protein networks by
RT   linking PAR-1 with MST1/2.";
RL   Genes Dev. 30:2696-2709(2016).
RN   [22]
RP   FUNCTION, AND INTERACTION WITH DCAF13; ESR1 AND DCAF1.
RX   PubMed=28068668; DOI=10.1038/nature20829;
RA   Britschgi A., Duss S., Kim S., Couto J.P., Brinkhaus H., Koren S.,
RA   De Silva D., Mertz K.D., Kaup D., Varga Z., Voshol H., Vissieres A.,
RA   Leroy C., Roloff T., Stadler M.B., Scheel C.H., Miraglia L.J., Orth A.P.,
RA   Bonamy G.M., Reddy V.A., Bentires-Alj M.;
RT   "The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk
RT   with ERalpha.";
RL   Nature 541:541-545(2017).
RN   [23]
RP   INTERACTION WITH SCRIB.
RX   PubMed=28169360; DOI=10.1038/srep42125;
RA   Liu J., Li J., Li P., Wang Y., Liang Z., Jiang Y., Li J., Feng C., Wang R.,
RA   Chen H., Zhou C., Zhang J., Yang J., Liu P.;
RT   "Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo
RT   signaling pathway.";
RL   Sci. Rep. 7:42125-42125(2017).
RN   [24]
RP   VARIANTS [LARGE SCALE ANALYSIS] TRP-96; GLY-204; GLN-237; TRP-370; SER-531;
RP   LEU-641; ILE-669; PRO-806 AND SER-1000.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Negative regulator of YAP1 in the Hippo signaling pathway
CC       that plays a pivotal role in organ size control and tumor suppression
CC       by restricting proliferation and promoting apoptosis. The core of this
CC       pathway is composed of a kinase cascade wherein STK3/MST2 and
CC       STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates
CC       and activates LATS1/2 in complex with its regulatory protein MOB1,
CC       which in turn phosphorylates and inactivates YAP1 oncoprotein and
CC       WWTR1/TAZ. Phosphorylation of YAP1 by LATS1 inhibits its translocation
CC       into the nucleus to regulate cellular genes important for cell
CC       proliferation, cell death, and cell migration. Acts as a tumor
CC       suppressor which plays a critical role in maintenance of ploidy through
CC       its actions in both mitotic progression and the G1 tetraploidy
CC       checkpoint. Negatively regulates G2/M transition by down-regulating
CC       CDK1 kinase activity. Involved in the control of p53 expression.
CC       Affects cytokinesis by regulating actin polymerization through negative
CC       modulation of LIMK1. May also play a role in endocrine function. Plays
CC       a role in mammary gland epithelial cell differentiation, both through
CC       the Hippo signaling pathway and the intracellular estrogen receptor
CC       signaling pathway by promoting the degradation of ESR1
CC       (PubMed:28068668). {ECO:0000269|PubMed:10518011,
CC       ECO:0000269|PubMed:10831611, ECO:0000269|PubMed:15122335,
CC       ECO:0000269|PubMed:15220930, ECO:0000269|PubMed:18158288,
CC       ECO:0000269|PubMed:19927127, ECO:0000269|PubMed:28068668}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:10518011, ECO:0000269|PubMed:15122335};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:10518011,
CC         ECO:0000269|PubMed:15122335};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- SUBUNIT: Complexes with CDK1 in early mitosis (PubMed:9988268). LATS1-
CC       associated CDK1 has no mitotic cyclin partner and no apparent kinase
CC       activity (PubMed:9988268). Binds phosphorylated ZYX, locating this
CC       protein to the mitotic spindle and suggesting a role for actin
CC       regulatory proteins during mitosis (PubMed:10831611). Binds to and
CC       colocalizes with LIMK1 at the actomyosin contractile ring during
CC       cytokinesis (PubMed:15220930). Interacts (via PPxY motif 2) with YAP1
CC       (via WW domains) (PubMed:18158288). Interacts with MOB1A and MOB1B
CC       (PubMed:19739119). Interacts with LIMD1, WTIP and AJUBA
CC       (PubMed:20303269). Interacts with ESR1, DCAF1 and DCAF13; probably
CC       recruits DCAF1 and DCAF13 to ESR1 to promote ESR1 ubiquitination and
CC       ubiquitin-mediated proteasomal degradation (PubMed:28068668). Interacts
CC       with STK3/MST2; this interaction is inhibited in the presence of DLG5
CC       (PubMed:28087714). Interacts with SCRIB in the presence of DLG5
CC       (PubMed:28169360). Interacts with WWTR1/TAZ (By similarity).
CC       {ECO:0000250|UniProtKB:Q8BYR2, ECO:0000269|PubMed:10831611,
CC       ECO:0000269|PubMed:15220930, ECO:0000269|PubMed:18158288,
CC       ECO:0000269|PubMed:19739119, ECO:0000269|PubMed:20303269,
CC       ECO:0000269|PubMed:28068668, ECO:0000269|PubMed:28087714,
CC       ECO:0000269|PubMed:28169360, ECO:0000269|PubMed:9988268}.
CC   -!- INTERACTION:
CC       O95835; P06493: CDK1; NbExp=3; IntAct=EBI-444209, EBI-444308;
CC       O95835; P24941: CDK2; NbExp=4; IntAct=EBI-444209, EBI-375096;
CC       O95835; Q9Y4B6: DCAF1; NbExp=4; IntAct=EBI-444209, EBI-1996353;
CC       O95835; P03372: ESR1; NbExp=2; IntAct=EBI-444209, EBI-78473;
CC       O95835; P53667: LIMK1; NbExp=5; IntAct=EBI-444209, EBI-444403;
CC       O95835; Q9H8S9: MOB1A; NbExp=9; IntAct=EBI-444209, EBI-748229;
CC       O95835; Q7L9L4: MOB1B; NbExp=7; IntAct=EBI-444209, EBI-2558745;
CC       O95835; P35240: NF2; NbExp=4; IntAct=EBI-444209, EBI-1014472;
CC       O95835; O60285: NUAK1; NbExp=2; IntAct=EBI-444209, EBI-1046789;
CC       O95835; O43255: SIAH2; NbExp=2; IntAct=EBI-444209, EBI-948141;
CC       O95835; Q15831: STK11; NbExp=2; IntAct=EBI-444209, EBI-306838;
CC       O95835; Q9GZV5: WWTR1; NbExp=5; IntAct=EBI-444209, EBI-747743;
CC       O95835; P46937: YAP1; NbExp=10; IntAct=EBI-444209, EBI-1044059;
CC       O95835; Q15942: ZYX; NbExp=10; IntAct=EBI-444209, EBI-444225;
CC       O95835; P46662: Nf2; Xeno; NbExp=5; IntAct=EBI-444209, EBI-644586;
CC       O95835-2; O15145: ARPC3; NbExp=3; IntAct=EBI-17978514, EBI-351829;
CC       O95835-2; Q9UHD9: UBQLN2; NbExp=3; IntAct=EBI-17978514, EBI-947187;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome {ECO:0000269|PubMed:10518011}. Cytoplasm,
CC       cytoskeleton, spindle {ECO:0000269|PubMed:10518011}. Midbody
CC       {ECO:0000269|PubMed:10518011}. Cytoplasm, cytoskeleton, microtubule
CC       organizing center, spindle pole body {ECO:0000269|PubMed:10518011}.
CC       Note=Localizes to the centrosomes throughout interphase but migrates to
CC       the mitotic apparatus, including spindle pole bodies, mitotic spindle,
CC       and midbody, during mitosis. {ECO:0000269|PubMed:10518011}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1 {ECO:0000269|PubMed:9988268};
CC         IsoId=O95835-1; Sequence=Displayed;
CC       Name=2 {ECO:0000305};
CC         IsoId=O95835-2; Sequence=VSP_051604, VSP_051605;
CC   -!- TISSUE SPECIFICITY: Expressed in all adult tissues examined except for
CC       lung and kidney. {ECO:0000269|PubMed:10518011}.
CC   -!- PTM: Autophosphorylated and phosphorylated during M-phase of the cell
CC       cycle (PubMed:9988268, PubMed:10518011, PubMed:15122335).
CC       Phosphorylated by STK3/MST2 at Ser-909 and Thr-1079, which results in
CC       its activation (PubMed:15688006). Phosphorylation at Ser-464 by NUAK1
CC       and NUAK2 leads to decreased protein level and is required to regulate
CC       cellular senescence and cellular ploidy (PubMed:19927127).
CC       {ECO:0000269|PubMed:10518011, ECO:0000269|PubMed:15122335,
CC       ECO:0000269|PubMed:15688006, ECO:0000269|PubMed:19927127,
CC       ECO:0000269|PubMed:9988268}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/LATS1ID41127ch6q25.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF104413; AAD16882.1; -; mRNA.
DR   EMBL; AF164041; AAD50272.1; -; mRNA.
DR   EMBL; BC002767; AAH02767.1; -; mRNA.
DR   CCDS; CCDS34551.1; -. [O95835-1]
DR   CCDS; CCDS59040.1; -. [O95835-2]
DR   RefSeq; NP_001257448.1; NM_001270519.1. [O95835-2]
DR   RefSeq; NP_004681.1; NM_004690.3. [O95835-1]
DR   PDB; 4ZRK; X-ray; 2.32 A; E/F/G/H=69-100.
DR   PDB; 5B5W; X-ray; 2.96 A; U=622-704.
DR   PDB; 5BRK; X-ray; 2.30 A; B=602-704.
DR   PDB; 7LWH; X-ray; 1.61 A; B=69-91.
DR   PDBsum; 4ZRK; -.
DR   PDBsum; 5B5W; -.
DR   PDBsum; 5BRK; -.
DR   PDBsum; 7LWH; -.
DR   AlphaFoldDB; O95835; -.
DR   SMR; O95835; -.
DR   BioGRID; 114563; 250.
DR   CORUM; O95835; -.
DR   DIP; DIP-31516N; -.
DR   IntAct; O95835; 63.
DR   MINT; O95835; -.
DR   STRING; 9606.ENSP00000437550; -.
DR   BindingDB; O95835; -.
DR   ChEMBL; CHEMBL6167; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; O95835; -.
DR   iPTMnet; O95835; -.
DR   PhosphoSitePlus; O95835; -.
DR   BioMuta; LATS1; -.
DR   EPD; O95835; -.
DR   jPOST; O95835; -.
DR   MassIVE; O95835; -.
DR   MaxQB; O95835; -.
DR   PaxDb; O95835; -.
DR   PeptideAtlas; O95835; -.
DR   PRIDE; O95835; -.
DR   ProteomicsDB; 51081; -. [O95835-1]
DR   ProteomicsDB; 51082; -. [O95835-2]
DR   Antibodypedia; 33280; 405 antibodies from 31 providers.
DR   DNASU; 9113; -.
DR   Ensembl; ENST00000253339.9; ENSP00000253339.5; ENSG00000131023.13. [O95835-1]
DR   Ensembl; ENST00000392273.7; ENSP00000444678.1; ENSG00000131023.13. [O95835-2]
DR   Ensembl; ENST00000543571.6; ENSP00000437550.1; ENSG00000131023.13. [O95835-1]
DR   GeneID; 9113; -.
DR   KEGG; hsa:9113; -.
DR   MANE-Select; ENST00000543571.6; ENSP00000437550.1; NM_004690.4; NP_004681.1.
DR   UCSC; uc003qmu.2; human. [O95835-1]
DR   CTD; 9113; -.
DR   DisGeNET; 9113; -.
DR   GeneCards; LATS1; -.
DR   HGNC; HGNC:6514; LATS1.
DR   HPA; ENSG00000131023; Low tissue specificity.
DR   MIM; 603473; gene.
DR   neXtProt; NX_O95835; -.
DR   OpenTargets; ENSG00000131023; -.
DR   PharmGKB; PA30301; -.
DR   VEuPathDB; HostDB:ENSG00000131023; -.
DR   eggNOG; KOG0608; Eukaryota.
DR   GeneTree; ENSGT00940000157684; -.
DR   HOGENOM; CLU_004885_0_0_1; -.
DR   InParanoid; O95835; -.
DR   OMA; YQSGDHA; -.
DR   OrthoDB; 759391at2759; -.
DR   PhylomeDB; O95835; -.
DR   TreeFam; TF351549; -.
DR   PathwayCommons; O95835; -.
DR   Reactome; R-HSA-2028269; Signaling by Hippo.
DR   SignaLink; O95835; -.
DR   SIGNOR; O95835; -.
DR   BioGRID-ORCS; 9113; 23 hits in 1120 CRISPR screens.
DR   ChiTaRS; LATS1; human.
DR   GeneWiki; LATS1; -.
DR   GenomeRNAi; 9113; -.
DR   Pharos; O95835; Tchem.
DR   PRO; PR:O95835; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; O95835; protein.
DR   Bgee; ENSG00000131023; Expressed in germinal epithelium of ovary and 181 other tissues.
DR   ExpressionAtlas; O95835; baseline and differential.
DR   Genevisible; O95835; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:UniProtKB-SubCell.
DR   GO; GO:0030496; C:midbody; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0000922; C:spindle pole; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030331; F:nuclear estrogen receptor binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:UniProtKB.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0051301; P:cell division; IEA:UniProtKB-KW.
DR   GO; GO:0051220; P:cytoplasmic sequestering of protein; IMP:BHF-UCL.
DR   GO; GO:0000082; P:G1/S transition of mitotic cell cycle; IBA:GO_Central.
DR   GO; GO:0000086; P:G2/M transition of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0035329; P:hippo signaling; IDA:BHF-UCL.
DR   GO; GO:0009755; P:hormone-mediated signaling pathway; ISS:UniProtKB.
DR   GO; GO:0001827; P:inner cell mass cell fate commitment; IEA:Ensembl.
DR   GO; GO:0001828; P:inner cell mass cellular morphogenesis; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0030216; P:keratinocyte differentiation; IEA:Ensembl.
DR   GO; GO:0060644; P:mammary gland epithelial cell differentiation; IMP:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0045736; P:negative regulation of cyclin-dependent protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:1900181; P:negative regulation of protein localization to nucleus; ISS:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IBA:GO_Central.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030833; P:regulation of actin filament polymerization; IDA:UniProtKB.
DR   GO; GO:0033146; P:regulation of intracellular estrogen receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0046620; P:regulation of organ growth; IBA:GO_Central.
DR   GO; GO:0043254; P:regulation of protein-containing complex assembly; IMP:BHF-UCL.
DR   GO; GO:0017015; P:regulation of transforming growth factor beta receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:2000058; P:regulation of ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0000819; P:sister chromatid segregation; IDA:UniProtKB.
DR   CDD; cd05625; STKc_LATS1; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR028741; LATS1.
DR   InterPro; IPR042706; LATS1_STKc.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR015940; UBA.
DR   InterPro; IPR009060; UBA-like_sf.
DR   PANTHER; PTHR24356:SF138; PTHR24356:SF138; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00627; UBA; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF46934; SSF46934; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50030; UBA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell cycle; Cell division;
KW   Cytoplasm; Cytoskeleton; Kinase; Magnesium; Metal-binding; Mitosis;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Tumor suppressor.
FT   CHAIN           1..1130
FT                   /note="Serine/threonine-protein kinase LATS1"
FT                   /id="PRO_0000086232"
FT   DOMAIN          100..141
FT                   /note="UBA"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00212"
FT   DOMAIN          705..1010
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   DOMAIN          1011..1090
FT                   /note="AGC-kinase C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00618"
FT   REGION          1..71
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          149..276
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          294..321
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          365..405
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          432..484
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          515..631
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          526..655
FT                   /note="Interaction with YAP1"
FT                   /evidence="ECO:0000269|PubMed:18158288"
FT   REGION          1104..1130
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           373..376
FT                   /note="PPxY motif 1"
FT   MOTIF           556..559
FT                   /note="PPxY motif 2"
FT   COMPBIAS        17..38
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        39..59
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        163..183
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        200..215
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        232..270
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        295..310
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        381..405
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        515..537
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        549..565
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        583..631
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        828
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:P22612,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159, ECO:0000255|PROSITE-
FT                   ProRule:PRU10027"
FT   BINDING         711..719
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000250|UniProtKB:P22612,
FT                   ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         734
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:15122335"
FT   MOD_RES         246
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         278
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         464
FT                   /note="Phosphoserine; by NUAK1 and NUAK2"
FT                   /evidence="ECO:0000269|PubMed:19927127,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         613
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         674
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17525332"
FT   MOD_RES         909
FT                   /note="Phosphoserine; by STK3/MST2"
FT                   /evidence="ECO:0000269|PubMed:15688006"
FT   MOD_RES         1079
FT                   /note="Phosphothreonine; by STK3/MST2"
FT                   /evidence="ECO:0000269|PubMed:15688006,
FT                   ECO:0000269|PubMed:28087714"
FT   VAR_SEQ         672..690
FT                   /note="GLSQDAQDQMRKMLCQKES -> KPFKMSIFILNHLFAWCLF (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_051604"
FT   VAR_SEQ         691..1130
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_051605"
FT   VARIANT         96
FT                   /note="R -> W (in dbSNP:rs55945045)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040660"
FT   VARIANT         204
FT                   /note="S -> G (in dbSNP:rs34793526)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040661"
FT   VARIANT         237
FT                   /note="P -> Q (in dbSNP:rs56149740)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040662"
FT   VARIANT         370
FT                   /note="R -> W (in dbSNP:rs56348064)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040663"
FT   VARIANT         531
FT                   /note="P -> S (in dbSNP:rs55874734)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040664"
FT   VARIANT         641
FT                   /note="F -> L (in dbSNP:rs35163691)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040665"
FT   VARIANT         669
FT                   /note="M -> I (in a lung adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs1390558952)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040666"
FT   VARIANT         806
FT                   /note="R -> P (in a lung large cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040667"
FT   VARIANT         1000
FT                   /note="G -> S (in dbSNP:rs56412005)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_040668"
FT   MUTAGEN         464
FT                   /note="S->A: Abolishes phosphorylation by NUAK1 and NUAK2."
FT                   /evidence="ECO:0000269|PubMed:19927127"
FT   MUTAGEN         559
FT                   /note="Y->F: Loss of interaction with YAP1."
FT                   /evidence="ECO:0000269|PubMed:18158288"
FT   MUTAGEN         734
FT                   /note="K->A: Loss of kinase activity, autophosphorylation,
FT                   increased ploidy, prolonged duration of mitosis and lack of
FT                   p53 expression."
FT                   /evidence="ECO:0000269|PubMed:15122335"
FT   HELIX           72..74
FT                   /evidence="ECO:0007829|PDB:7LWH"
FT   HELIX           75..85
FT                   /evidence="ECO:0007829|PDB:7LWH"
FT   HELIX           86..88
FT                   /evidence="ECO:0007829|PDB:7LWH"
FT   HELIX           637..671
FT                   /evidence="ECO:0007829|PDB:5BRK"
FT   HELIX           675..697
FT                   /evidence="ECO:0007829|PDB:5BRK"
SQ   SEQUENCE   1130 AA;  126870 MW;  11CFBCD8FD87DCD8 CRC64;
     MKRSEKPEGY RQMRPKTFPA SNYTVSSRQM LQEIRESLRN LSKPSDAAKA EHNMSKMSTE
     DPRQVRNPPK FGTHHKALQE IRNSLLPFAN ETNSSRSTSE VNPQMLQDLQ AAGFDEDMVI
     QALQKTNNRS IEAAIEFISK MSYQDPRREQ MAAAAARPIN ASMKPGNVQQ SVNRKQSWKG
     SKESLVPQRH GPPLGESVAY HSESPNSQTD VGRPLSGSGI SAFVQAHPSN GQRVNPPPPP
     QVRSVTPPPP PRGQTPPPRG TTPPPPSWEP NSQTKRYSGN MEYVISRISP VPPGAWQEGY
     PPPPLNTSPM NPPNQGQRGI SSVPVGRQPI IMQSSSKFNF PSGRPGMQNG TGQTDFMIHQ
     NVVPAGTVNR QPPPPYPLTA ANGQSPSALQ TGGSAAPSSY TNGSIPQSMM VPNRNSHNME
     LYNISVPGLQ TNWPQSSSAP AQSSPSSGHE IPTWQPNIPV RSNSFNNPLG NRASHSANSQ
     PSATTVTAIT PAPIQQPVKS MRVLKPELQT ALAPTHPSWI PQPIQTVQPS PFPEGTASNV
     TVMPPVAEAP NYQGPPPPYP KHLLHQNPSV PPYESISKPS KEDQPSLPKE DESEKSYENV
     DSGDKEKKQI TTSPITVRKN KKDEERRESR IQSYSPQAFK FFMEQHVENV LKSHQQRLHR
     KKQLENEMMR VGLSQDAQDQ MRKMLCQKES NYIRLKRAKM DKSMFVKIKT LGIGAFGEVC
     LARKVDTKAL YATKTLRKKD VLLRNQVAHV KAERDILAEA DNEWVVRLYY SFQDKDNLYF
     VMDYIPGGDM MSLLIRMGIF PESLARFYIA ELTCAVESVH KMGFIHRDIK PDNILIDRDG
     HIKLTDFGLC TGFRWTHDSK YYQSGDHPRQ DSMDFSNEWG DPSSCRCGDR LKPLERRAAR
     QHQRCLAHSL VGTPNYIAPE VLLRTGYTQL CDWWSVGVIL FEMLVGQPPF LAQTPLETQM
     KVINWQTSLH IPPQAKLSPE ASDLIIKLCR GPEDRLGKNG ADEIKAHPFF KTIDFSSDLR
     QQSASYIPKI THPTDTSNFD PVDPDKLWSD DNEEENVNDT LNGWYKNGKH PEHAFYEFTF
     RRFFDDNGYP YNYPKPIEYE YINSQGSEQQ SDEDDQNTGS EIKNRDLVYV
//
